PMV Pharmaceuticals, Inc.
NASDAQ:PMVP · NASDAQ Global Select
+$0.02 today
Vol 0.12M · Avg 0.39M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-74.2%
avg -15.3%
ROIC
-79.5%
avg -33.3%
ROA
-66.7%
avg -28.9%
Analysis
ROA is currently the strongest return metric at -66.7% versus its period average of -28.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David H. Mack | Co-Founder, Chief Executive Officer, President & Director | $912,871.00 | — | 64 | $744,960.00 | 1.40% |
Deepika Jalota | Chief Development Officer | $653,067.00 | — | 49 | $303,310.00 | 0.57% |
Robert Ticktin | General Counsel, Chief Operating Officer & Company Secretary | $612,000.00 | — | 64 | $319,270.00 | 0.60% |
Michael Carulli | Chief Financial Officer | $532,801.00 | — | 52 | $240,000.00 | 0.45% |
Arnold J. Levine | Co-Founder, Independent Director & Member of Scientific Advisory Board | $140,000.00 | — | 86 | $42,000.00 | 0.08% |
Tim Smith | Senior Vice President and Head of Corporate Development & Investor Relations | — | — | — | — | — |
Laura De Leon | VP & Head of Clinical Development Operations | — | — | — | — | — |
Binh Vu | Senior Vice President of Drug Discovery & CMC | — | — | — | — | — |
Marc Fellous | Senior Vice President and Head of Clinical Development & Medical Affairs | — | — | — | — | — |
Crystal Zuckerman | Vice President of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
6
$2.57M
Net Sentiment
$2.57M
Net selling
Most Active
ORBIMED ADVISORS LLC
2 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 6 sells worth $2.57M over the last 12 months. That adds up to net selling of $2.57M. ORBIMED ADVISORS LLC was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$487.67M
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Vaxart, Inc.
NASDAQ:VXRT
$135.55M
Repare Therapeutics Inc.
RPTX
$114.24M
Biomea Fusion, Inc.
NASDAQ:BMEA
$69.61M
Cibus, Inc.
NASDAQ:CBUS
$55.95M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.71M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
aTyr Pharma, Inc.
ATYR
$43.18M
Lite Strategy, Inc.
LITS
$25.22M
Who manages PMVP?
PMV Pharmaceuticals, Inc. (PMVP) lists 10 active executives. The top listed executive is Arnold J. Levine, Co-Founder, Independent Director & Member of Scientific Advisory Board.
Are PMVP insiders buying or selling?
Recent insider activity shows net selling of $26.44M.
Explore More
Continue the stock analysis
Jump to another research area for this company.